Phase 2 Rheumatoid Arthritis Trial, Recruiting

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

• People diagnosed with rheumatoid arthritis (RA) for at least 3 months before the screening visit, based on recognised international classification guidelines
• People aged between 18 and 85 years old
• People whose RA is currently active, shown by a specific disease activity score (DAS28-CRP), with at least 3 swollen joints, at least 3 tender joints, and a raised inflammation marker (CRP) confirmed at screening
• People who have been taking a standard RA medication (called a csDMARD) at a stable dose for at least 4 weeks, and who have been on that medication for at least 3 months in total

Who may not be able to join:

• People whose RA is severe enough that a doctor considers it necessary to start a stronger biological or targeted medication immediately
• People for whom the trial drug (CIT-013) is medically unsuitable (confirm with trial site for specific details)
• People who have another active inflammatory joint condition alongside RA, although those with Sjögren's syndrome that is currently active may still be considered
• People who have recently used certain RA biological or targeted medications and have not waited long enough before joining — the required waiting periods are: at least 1 week after etanercept; at least 4 weeks after adalimumab, infliximab, certolizumab, golimumab, abatacept, tocilizumab, or sarilumab; at least 6 months after rituximab; and at least 2 weeks after targeted synthetic DMARDs
• People who have previously been treated with 3 or more biological or targeted RA medications
• People who have had a steroid injection, or who have been taking more than 10 mg per day of oral prednisolone (or an equivalent steroid), within the 4 weeks before screening

Important: Always verify eligibility with the trial site directly before applying.